Test Directory
| Test Code | ||
| BRAF | ||
| Test Name | ||
| BRAF V600 Variant Analysis by PCR | ||
| CPT Codes | ||
| 81210, G0452 | ||
| Expected Turnaround Time | ||
| 1 - 7 days | ||
| Clinical Utility | ||
|
BRAF, a serine-threonine protein kinase, is a central mediator in signaling cascades leading to cell cycling and cell growth. Oncogenic BRAF mutations have been found in approximately 8-15% of colorectal cancers; 1-4% of non-small cell lung carcinoma; 50% of melanoma cases. The most frequently identified activating BRAF mutations involves codon 600 in exon 15; primarily V600E. The result of these mutations is enhanced BRAF kinase activity and increased phosphorylation of downstream targets, promoting cell proliferation. Results from BRAF Mutation analyses of patient carcinomas and melanomas can help in patient treatment decisions regarding the administration of anti-EGFR treatments, and BRAF inhibitor therapy. |
||
| Specimen and Container Info | ||
|
Specimen Type: FFPE Block |
||
| Processing and Submission Instructions | ||
|
||
| Transport Instructions | ||
|
Transport to the laboratory at room temperature. |
||
| Stability Requirements | ||
|
||
| Causes for Rejection | ||
|
Specimens with less than 5% tumor content will be rejected. |
||
| Methodology | ||
| Polymerase Chain Reaction (PCR) | ||
| Reference Intervals | ||
|
BRAF Wild Type |
||
| Limitations | ||
|
BRAF Mutations (Targeted Variants):
|
||
| Performing Location | ||
| Roble Road Core Laboratory | ||
| Alternate Names | ||
|
||
| Description | ||
|
BRAF Mutations (Targeted Variants):
|
||
| Testing Schedule | ||
| Routine, Monday - Friday no holidays | ||
| Genes | ||
| BRAF Mutations (Targeted Variants): c.1799T>A (p.Val600Glu; V600E), c.1798_1799delinsAA (p.Val600Lys; V600K) and c.1798_1799delinsAG (p.Val600Arg; V600R) | ||
The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. View the Terms.
© 2026 HNL Lab Medicine. All rights reserved.